

Paola Matteucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7965481/publications.pdf>

Version: 2024-02-01

35
papers

4,125
citations

361045

20
h-index

395343

33
g-index

35
all docs

35
docs citations

35
times ranked

5486
citing authors

#	ARTICLE	IF	CITATIONS
1	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
2	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. Journal of Geriatric Oncology, 2020, 11, 37-40.	0.5	14
3	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia, 2019, 33, 1047-1051.	3.3	27
4	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.4	35
5	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Annals of Oncology, 2015, 26, 167-172.	0.6	17
6	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. Clinical Genitourinary Cancer, 2014, 12, 196-202.e1.	0.9	3
7	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplantation, 2014, 49, 485-491.	1.3	10
8	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. Journal of Clinical Oncology, 2013, 31, 2974-2976.	0.8	14
9	Phase <sc>II</sc> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	1.2	36
10	Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. American Journal of Blood Research, 2012, 2, 105-12.	0.6	0
11	Radioimmunotherapy and secondary leukemia: A case report. Leukemia Research, 2010, 34, e1-e4.	0.4	4
12	Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplantation, 2010, 45, 1119-1120.	1.3	9
13	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leukemia and Lymphoma, 2010, 51, 1251-1259.	0.6	34
14	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplantation, 2009, 43, 509-511.	1.3	25
15	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 2009, 113, 18-27.	0.6	99
16	High-Dose Yttrium-90â€“Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2008, 26, 5175-5182.	0.8	68
17	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia, 2007, 21, 2316-2323.	3.3	142
18	Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 1270-1276.	2.0	55

#	ARTICLE	IF	CITATIONS
19	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. <i>British Journal of Cancer</i> , 2006, 94, 1016-1020.	2.9	39
20	High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.	1.2	35
21	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.	0.6	47
22	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.	1.7	11
23	Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002, 100, 1104-1105.	0.6	58
24	Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002, 99, 3838-3843.	0.6	2,907
25	High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. <i>Bone Marrow Transplantation</i> , 2002, 30, 725-732.	1.3	47
26	Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002, 26, 1131-1133.	0.4	36
27	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	201
28	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	1
29	Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. <i>Transfusion</i> , 1999, 39, 48-55.	0.8	46
30	Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. <i>Bone Marrow Transplantation</i> , 1999, 23, 323-327.	1.3	19
31	Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. <i>Gene Therapy</i> , 1998, 5, 465-472.	2.3	38
32	Isolated Left Ventricular Filling Abnormalities May Predict Interleukin-2-Induced Cardiovascular Toxicity. <i>Journal of Immunotherapy</i> , 1996, 19, 134-141.	1.2	9
33	Serum Levels of Soluble Cell Adhesion Molecules (ICAM-1, VCAM-1, E-Selectin) and of Cytokine TNF- α Increase during Interleukin-2 Therapy. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 142-147.	2.1	10
34	Intrapleural Administration of Interleukin-2 and Lak Cells in Locally Advanced Non-Small-Cell Lung Cancer. A Case Report. <i>Tumori</i> , 1994, 80, 246-250.	0.6	2
35	Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α -interferon. <i>European Journal of Cancer</i> , 1994, 30, 1292-1298.	1.3	23